Healthcare
Takara Bio Inc.(TKBIF)
Live Price
Offline$7.30
+0.00% today
1Y Change
-68.53%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $137.39B
- Revenue Growth
- 0.0%
- EPS Growth
- 0.0%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Takara Bio Inc. (TKBIF) is a Healthcare stock with a market cap of $137.39B and listed on OTC. The stock last traded around $7.30 and down 68.5% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow 0.0% with operating margin -2.5% and ROIC -0.9%. Valuation is more restrained than many high-expectation growth names at price/sales 3.1. Stock Foundry combines TKBIF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-2.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is 0.0%, while operating margin sits near -2.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +15.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 May 11, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Feb 13, 2026 | โ | +0.0% | +46.0% | +46.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TKBIF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TKBIF Max Drawdown
-78.45%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TKBIF and SPY.
Company Overview
Takara Bio Inc.
Other OTC
Takara Bio Inc., together with its subsidiaries, engages in bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses in Japan, China, rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including genetic research reagents and testing kits; products related to coronavirus testing comprising in vitro diagnostics that detect viruses; analytical reagents; single-cell analysis systems; gene expression research reagents; fluorescent proteins series; genome-editing research reagents; iPS cell research reagents; and products for stem cell culturing and induction of differentiation under the TaKaRa, Clontech, and Cellartis brand names. It also provides contract services for regenerative medicine products, such as manufacturing of viral vectors and gene-transduced cells, quality and safety testing, and cell banking; and contract services for gene analysis and testing, including sequencing, intestinal flora analysis, comprehensive analysis of cancer-associated genes, and cell line creation through genome editing. In addition, the company is involved in developing platform technology for biologics development in areas, such as gene therapy. The company was incorporated in 2002 and is based in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.
- Leadership
- Tsuyoshi Miyamura
- IPO Date
- Apr 27, 2020
- Employees
- 1.8k
- Street Address
- 7-4-38 Nojihigashi
- Mailing
- Kusatsu, 525-0058
- Region
- Kusatsu, JP
- Reporting Currency
- USD
- Investor Line
- 81 77 565 6920
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 3.1
- Price/Book
- 1.4
Growth
- Revenue
- 0.0%
- EPS
- 0.0%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- 54.0%
- Operating Margin
- -2.5%
- Net Margin
- -16.3%
- ROE
- -6.7%
- ROIC
- -0.9%
Balance Sheet
- Debt/Equity
- 0.10
- Current Ratio
- 5.47
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.